Search

Displaying results 3501 - 3510 of 10000 in total
  1. Drug

    Catridecacog

    go.drugbank.com/drugs/DB09310
    Approved

    Coagulation Factor XIII A-Subunit (Recombinant) is available in the US as the commmercially available product Tretten, and in the EU as NovoThirteen. … When activated by thrombin at the site of injury, the FXIII A2B2 pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit.

  2. Drug

    Rotigotine

    go.drugbank.com/drugs/DB05271
    ApprovedInvestigational

    In 1998 Aderis licensed worldwide development and commercialization rights to Schwarz Pharma of Germany. It was approved by the European Medicines Agency in 2006 and by the FDA in 2007. … It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours.

    Products: NEUPRO® 6 MG/24 H, NEUPRO® 4 MG /24 H
  3. Drug

    Artemisia tridentata pollen

    go.drugbank.com/drugs/DB10390
    Approved

    Artemisia tridentata pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS128872
  4. Drug

    Sinapultide

    go.drugbank.com/drugs/DB11332
    ApprovedWithdrawn

    [L2504] Windtree is currently developing aerosolized KL4 surfactant to treat RDS in premature infants, and thereafter, to potentially address a range of indications in neonatal, pediatric and adult … [L2502] Windtree Therapeutics plans a phase III trial for Respiratory distress syndrome in 2018.

  5. Drug

    Forasartan

    go.drugbank.com/drugs/DB01342
    Experimental

    Forasartan competes with angiotensin II for binding at the AT1 receptor subtype. … As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance.

    Categories: Agents Acting on the Renin-Angiotensin System
  6. Drug

    Halofantrine

    go.drugbank.com/drugs/DB01218
    ApprovedWithdrawn

    Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. … It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste.

  7. Drug

    Ethoheptazine

    go.drugbank.com/drugs/DB08988
    ApprovedWithdrawn

    It is a phenazepine based opioid analgesic. It was invented in the 1950s and is related to other drugs such as proheptazine. Ethoheptazine is no longer marketed in the United States.

  8. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    It was developed by Novartis and was granted FDA approval on November 15, 2019. … [L10097] While crizanlizumab received conditional marketing authorization from the EMA in October 2020, this approval was revoked in August 2023 due to concerns over the efficacy and safety of the drug

  9. Drug

    Bamipine

    go.drugbank.com/drugs/DB13489
    Investigational

    Bamipine is a first-generation antihistamine.

    Categories: Antihistamines, Anesthetics, Etc.
  10. Drug

    Tedisamil

    go.drugbank.com/drugs/DB06200
    Experimental

    Tedisamil (planned trade name Pulzium) is an investigational drug for atrial fibrillation and atrial flutter. … It is currently being developed by Solvay and is currently under regulatory review by the United States Food and Drug Administration.

    Categories: Compounds used in a research, industrial, or household setting